Aim: To examine neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in prognosticating immunotherapy efficacy. Methods: A retrospective study of 156 patients with metastatic melanoma and non-small-cell lung cancer on PD-1 inhibitors. Results: Baseline NLR ≥5 was associated with worse progression-free survival (hazard ratio [HR]: 1.53; 95% CI: 1.01-2.31; p = 0.043) but nonsignificant worse overall survival trend (HR: 1.51; 95% CI: 0.98-2.34; p = 0.064). PLR ≥200 was associated with worse overall survival (HR: 1.94; 95% CI: 1.29-2.94; p = 0.002) and worse progression-free survival (HR: 1.894; 95% CI: 1.27-2.82; p = 0.002). NLR or PLR are prognosticating factors regardless of cancer types, with PLR having a stronger association with outcomes than NLR. Conclusion: High baseline NLR or PLR (alone and combined) were associated with worse immunotherapy efficacy regardless of cancer type, indicating their potential role as an agnostic marker for immunotherapy efficacy.
Aim: To examine neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in prognosticating immunotherapy efficacy. Methods: A retrospective study of 156 patients with metastatic melanoma and non-small-cell lung cancer on PD-1 inhibitors. Results: Baseline NLR ≥5 was associated with worse progression-free survival (hazard ratio [HR]: 1.53; 95% CI: 1.01-2.31; p = 0.043) but nonsignificant worse overall survival trend (HR: 1.51; 95% CI: 0.98-2.34; p = 0.064). PLR ≥200 was associated with worse overall survival (HR: 1.94; 95% CI: 1.29-2.94; p = 0.002) and worse progression-free survival (HR: 1.894; 95% CI: 1.27-2.82; p = 0.002). NLR or PLR are prognosticating factors regardless of cancer types, with PLR having a stronger association with outcomes than NLR. Conclusion: High baseline NLR or PLR (alone and combined) were associated with worse immunotherapy efficacy regardless of cancer type, indicating their potential role as an agnostic marker for immunotherapy efficacy.
Authors: Michele Guida; Nicola Bartolomeo; Davide Quaresmini; Pietro Quaglino; Gabriele Madonna; Jacopo Pigozzo; Anna Maria Di Giacomo; Alessandro Marco Minisini; Marco Tucci; Francesco Spagnolo; Marcella Occelli; Laura Ridolfi; Paola Queirolo; Ivana De Risi; Monica Valente; Angela Monica Sciacovelli; Vanna Chiarion Sileni; Paolo Antonio Ascierto; Lucia Stigliano; Sabino Strippoli Journal: J Transl Med Date: 2022-04-05 Impact factor: 5.531
Authors: Corinne A Calo; David A Barrington; Morgan Brown; Lynette Gonzalez; Jae Baek; Allison Huffman; Jason Benedict; Floor Backes; Laura Chambers; David Cohn; Larry Copeland; Casey Cosgrove; Christa Nagel; David O'Malley; Kristin Bixel Journal: Gynecol Oncol Rep Date: 2022-07-08
Authors: Caterina Gianni; Michela Palleschi; Giuseppe Schepisi; Chiara Casadei; Sara Bleve; Filippo Merloni; Marianna Sirico; Samanta Sarti; Lorenzo Cecconetto; Giandomenico Di Menna; Francesco Schettini; Ugo De Giorgi Journal: Front Oncol Date: 2022-08-08 Impact factor: 5.738